Loading clinical trials...
Loading clinical trials...
A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, LONG-TERM SAFETY STUDY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Conditions
Interventions
Tanezumab
Tanezumab
+1 more
Locations
18
United States
Jem Research, LLC
Atlantis, Florida, United States
Medical Specialists of the Palm Beaches
Atlantis, Florida, United States
Clinical Physiology Associates, Clinical Study Center
Fort Myers, Florida, United States
Harris Bonnette, MD
Fort Myers, Florida, United States
Arthritis & Rheumatic Care Center
South Miami, Florida, United States
Miami Research Associates
South Miami, Florida, United States
Start Date
February 15, 2010
Primary Completion Date
November 11, 2010
Completion Date
November 11, 2010
Last Updated
February 8, 2021
NCT07153471
NCT07351968
NCT06381791
NCT06747494
NCT07327931
NCT06906939
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions